Skip to main content

Table 2 Initial treatment response to different initial afatinib doses

From: The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Variables All patients Afatinib 30 mg daily Afatinib 40 mg daily P value
Initial response to afatinib treatment -n (%)     0.1486
 Complete response 1 (2%) 1 (3%) 0 (0%)  
 Partial response 39 (81%) 21 (72%) 18 (95%)  
 Stable disease 8 (17%) 7 (24%) 1 (5%)  
Disease control rate with afatinib treatment (%) 48 (100%) 29 (100%) 19 (100%) 0.1486
Response rate with afatinib treatment (%) 40 (83%) 22 (76%) 18 (95%) 0.0862